{
    "clinical_study": {
        "@rank": "95693", 
        "arm_group": {
            "arm_group_label": "Tivozanib", 
            "arm_group_type": "Experimental", 
            "description": "Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn about the effect of the investigational agent\n      tivozanib on the control of the tumor growth in hepatocellular (liver) cancer. The\n      investigators also plan to collect information on the likelihood to develop side effects\n      while on this treatment. Tivozanib is an oral medication (pill) taken once a day. This\n      medication is designed to stop the tumor from developing new blood vessels."
        }, 
        "brief_title": "Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Cancer", 
        "condition_browse": {
            "mesh_term": "Liver Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Angiogenesis is the formation of new blood vessels. Angiogenesis is driven by cyokines\n      including vascular endothelial growth factor. Tivozanib is an oral medication that inhibits\n      vascular endothelial growth factor preventing tumor from developing new blood vessels.\n\n      The purpose of this study is to evaluate the effects of tivozanib on hepatocellular (liver)\n      cancer. Participants in the study take tivozanib daily at a dose of 1 mg for  1month. if\n      doing well the dose would be increased to 1.5 mg per day. Patients are monitored for\n      response using CT or MRI scans every 2months. In addition, patients will have blood draws to\n      evaluate the effects of tivozanib on blood vessels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1. Patients with measurable, histological diagnosis of HCC and whose disease is not\n        amenable to surgical or regional therapy.\n\n          1. Prior allowed therapy:\n\n               -  Surgery including hepatic resection\n\n                    1. Minimum of 4 weeks since any surgical procedure.\n\n                    2. Patients must have adequately recovered from surgery\n\n               -  Regional therapy\n\n                    1. Includes transarterial chemoembolization (TACE, DEB-TACE), percutaneous\n                       ethanol injection, radiofrequency/cryo ablation, Yttrium-90\n                       radioembolization\n\n                    2. More than 2 weeks must have lapsed from therapy\n\n                    3. There must be an indicator lesion outside the treated area or clear\n                       evidence of progression in the treated lesion, not amenable for further\n                       local therapies.\n\n                    4. Concomitant sorafenib with regional therapy is allowed as long as no\n                       evidence of progression on sorafenib\n\n               -  Prior adjuvant sorafenib is allowed, if completed more than 6 months prior to\n                  disease recurrence.\n\n          2. Adequate hematological, liver and metabolic organ function.\n\n          3. Signed informed consent.\n\n        Exclusion Criteria:\n\n          1. Patients with mixed histology or fibrolamellar variant.\n\n          2. Prior systemic therapy for metastatic disease\n\n          3. uncontrolled hypertension (HTN)\n\n          4. symptomatic heart failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807156", 
            "org_study_id": "IRB00061422", 
            "secondary_id": [
                "IRB00061422", 
                "WINSHIP2302-12"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Tivozanib", 
            "description": "Oral medication given daily. No placebo.", 
            "intervention_name": "Tivozanib", 
            "intervention_type": "Drug", 
            "other_name": "AV-951"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tivozanib", 
            "Advanced hepatocellular cancer", 
            "Angiogenesis"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "belray@meoy.edu", 
                "last_name": "Bassel El-Rayes, MD", 
                "phone": "404-778-3882"
            }, 
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30322"
                }, 
                "name": "Emory University, Winship Cancer Institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer", 
        "overall_contact": {
            "email": "belraye@emory.edu", 
            "last_name": "Bassel El-Rayes, MD", 
            "phone": "404-778-3882"
        }, 
        "overall_official": {
            "affiliation": "Emory University Winship Cancer Institute", 
            "last_name": "Bassel El-Rayes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of disease progression will be made using CT or MRI scan of the organ(s) with the target lesion(s).", 
            "measure": "Number of patients with advanced HCC(Hepatocellular cancer) receiving tivozanib who are free the proportion of patients with advanced HCC receiving tivozanib who are free from progression", 
            "safety_issue": "Yes", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807156"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Emory University", 
            "investigator_full_name": "Bassel El-Rayes", 
            "investigator_title": "Studu Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Measurable lesions:  Lesions that can be measured in at least one dimension as \u2265 20 mm with conventional CT scan techniques or as \u2265 10 mm with spiral CT scan.\nNon-measurable lesions: All other lesions including small lesions (longest diameter < 20 mm with conventional techniques) and other non-measurable lesions including: pleural effusions, ascites, and disease documented by indirect evidence (e.g. biochemical abnormalities).\nTarget lesions: All measurable lesions up to a maximum of 5 lesions. Target lesions are selected for their size and suitability for accurate repetitive measurements. The sum of the longest diameter of all target lesions will be calculated and reported as the baseline sum LD. This will be used as a reference to further quantify objective response.\nNon-target lesions: All other lesions are identified as non-target lesions and should be followed as present or absent.", 
            "measure": "Response rate based on RECIST criteria", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Emory University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Emory University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}